



**The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
November 1, 2022**

Therapeutic Class	Drug Name	DURB Recommendation*
Immunomodulators, Atopic Dermatitis		
	<i>Adbry (Subcutaneous) Injection</i>	P/PA
	<i>Cibinqo (Oral) Tablet</i>	NP/PA
GI Motility, Chronic		
	<i>Ibsrela (Oral) Tablet</i>	NP/PA
Acne Agents, Topical		
	<i>Winlevi (Topical) Cream</i>	NP/PA

*All recommendations apply to the PDL unless explicitly stated otherwise; DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers' Administered Drug List